Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study

医学 单克隆抗体 顶点(几何体) 临床研究阶段 药理学 内科学 单克隆 抗体 免疫学 不利影响 临床试验 病理 类风湿性关节炎 癌症研究 化疗 副作用(计算机科学)
作者
Philip J. Mease,Christopher T. Ritchlin,Laura C. Coates,Alexa P. Kollmeier,Bei Zhou,Yusang Jiang,Karen Bensley,Koeun Im,Rattandeep Batra,Soumya D. Chakravarty,Proton Rahman,Désirée M F M van der Heijde
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:84 (12): 1983-1994 被引量:15
标识
DOI:10.1016/j.ard.2025.08.006
摘要

OBJECTIVES: The APEX study evaluated the effects of guselkumab, a fully human, dual-acting monoclonal antibody able to bind CD64 and selectively inhibit the interleukin (IL)-23p19 subunit, on clinical and radiographic outcomes in active psoriatic arthritis (PsA). METHODS: APEX (ongoing, phase 3b, double-blind, placebo-controlled) randomised (5:7:7) biologic-naïve adults with active PsA (≥3 tender, ≥3 swollen joints; C-reactive protein ≥0.3 mg/dL; ≥2 erosive joints) to subcutaneous guselkumab 100 mg every 4 weeks (Q4W); guselkumab 100 mg at week 0, week 4, then every 8 weeks (Q8W); or placebo every 4 weeks. Primary (proportion of participants achieving ≥20% improvement in American College of Rheumatology response criteria [ACR20]) and major secondary (total PsA-modified van der Heijde-Sharp [vdH-S] score least squares mean [LSM] change from baseline) endpoints at week 24 were multiplicity-controlled for comparing each guselkumab group versus placebo. RESULTS: Among 1020 participants (Q4W: 273; Q8W: 371; placebo: 376), significantly greater proportions of participants receiving guselkumab Q4W (66.6%) and Q8W (68.3%) versus placebo (47.0%) achieved ACR20 at week 24 (both P < 0.001). Baseline mean total vdH-S scores were 26.7 to 27.7 across groups; guselkumab Q4W- and Q8W-treated participants exhibited significantly lower rates of radiographic progression versus placebo at week 24 (total vdH-S score LSM change: 0.55 and 0.54 vs 1.35; P = 0.002 and P < 0.001, respectively). Through week 24, 38.2%, 42.5%, and 37.3% of participants receiving guselkumab Q4W, Q8W, and placebo, respectively, had ≥1 adverse event, with no new safety signals. CONCLUSIONS: Guselkumab, a fully human monoclonal antibody able to bind CD64 and simultaneously inhibit the IL-23p19 subunit, provided significantly higher rates of clinical improvement and significant inhibition of structural damage progression versus placebo, with no new safety signals, at week 24 in biologic-naïve participants with active and erosive PsA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hawaii完成签到,获得积分10
刚刚
1秒前
3秒前
Yippee发布了新的文献求助10
4秒前
4秒前
4秒前
4秒前
5秒前
KoAkimiya完成签到 ,获得积分10
6秒前
wxzk发布了新的文献求助10
7秒前
地火丢发布了新的文献求助10
7秒前
科研通AI6.4的应助被yu采纳,获得10
8秒前
wztao发布了新的文献求助10
8秒前
8秒前
8秒前
大模型的应助被Nov2采纳,获得10
9秒前
9秒前
9秒前
活力幻儿发布了新的文献求助10
10秒前
fanhuaxuejin完成签到 ,获得积分10
10秒前
NexusExplorer的应助被123采纳,获得10
10秒前
10秒前
xx发布了新的文献求助10
11秒前
鱼干儿发布了新的文献求助10
11秒前
阿祥完成签到,获得积分10
11秒前
12秒前
会发光的小叶子的应助被李麟采纳,获得10
13秒前
水弘的应助被李麟采纳,获得10
13秒前
13秒前
13秒前
moonlighter发布了新的文献求助10
15秒前
鬼舞发布了新的文献求助10
16秒前
16秒前
烟花的应助被辛勤念之采纳,获得10
16秒前
深深完成签到,获得积分10
17秒前
123y发布了新的文献求助10
17秒前
地火丢完成签到,获得积分10
17秒前
Yippee完成签到,获得积分20
17秒前
健壮小天鹅完成签到,获得积分10
18秒前
Elle完成签到,获得积分20
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183449
求助须知:如何正确求助?哪些是违规求助? 9572834
关于积分的说明 21827509
捐赠科研通 7780646
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480371